In good news for those averse to injections, GLP-1 agonist medication is a step closer to being offered in oral pill form, ...

This was over 28 days in a phase 1 trial. The level of weight loss and the tolerability of the treatment at 100-milligram ...

AstraZeneca and Viking Therapeutics both presented encouraging data on their obesity pills. Meanwhile, here’s how Americans ...

Tirzepatide, known under the brand name Mounjaro is prescribed for type 2 diabetes, but has been shown in clinical trials to ...

Amid growing concerns over counterfeit weight loss medications, a local clinical trial may offer a safer alternative for ...

The company's latest presentation supports the idea that its lead program will make billions.

Nov. 6, 2024 – The FDA has updated the labels for all GLP-1 weight loss drugs with a warning about pulmonary aspiration ...

Novo Nordisk said the side effects in trials so far for its experimental obesity drug CagriSema were similar to its GLP-1 ...

Obesity pill data released by Viking Therapeutics Inc and AstraZeneca Plc at a big conference foreshadowed an increasingly ...

Here are the key points about Viking Therapeutics' oral obesity drug VK2735: Early-Stage Trial Results: All doses of VK2735 ...